Uncategorized
Bausch + Lomb begins phase 3 studies of glaucoma drug candidate
Bausch + Lomb has begun a pair of phase 3 clinical studies on latanoprostene bunod to reduce IOP in patients with glaucoma or ocular hypertension, according to a company news release.The drug candidate, licensed from Nicox and previously known as BOL-303259-X and NCX 116, is a nitric oxide-donating prostaglandin F2 alpha analog. The APOLLO and LUNAR studies are two separate randomized, multicenter, double-masked, parallel-group clinical studies that will be conducted in North America and Europe.